GEMoaB Monoclonals
# GEMoaB Monoclonals

GEMoaB is a biopharmaceutical company based in Dresden/Germany. The company has a broad pipeline of next generation immunotherapy product candidates for the treatment of advanced blood cancers and solid tumours in pre-clinical and clinical development. The company was founded in 2011 by the two university professors Gerhard Ehninger and Michael Bachmann.

## Company background

To overcome the limitations of current cellular immunotherapies, GEMoaB has established two cellular immunotherapy platforms, which are called UniCAR & RevCAR. These genetically modified T-cells can be rapidly and repeatedly turned on and off via dosing of so-called Targeting Modules (TMs), which crosslink UniCAR/RevCAR T-effector cells with malignant target cells. Upon cross-linkage, UniCAR/RevCAR T-cells are activated and expanded and eliminate malignant target cells. They can be rapidly turned off after TM withdrawal, promising to avoid T-effector cell exhaustion and to reduce potential side effects typically associated with CAR-T therapies.

## Scientific and strategic board

The company's scientific and strategic board is composed of: Gerhard Ehninger (Chairman), Michael Bachmann (Germany), Katy Rezvani (U.S.A.), Bob Löwenberg (The Netherlands) as well as Thomas de Maizière, Member of Parliament (Germany).

## Co-operations

Gemoab co-operates with a range of partners: its sister company Cellex in Cologne, Germany, the Fraunhofer-Institut, the pharmaceutical company Bristol-Myers Squibb as well as the companies ABX, Bio Elpida and the federal Saxonian Ministry of Science and Research.

## Drugs currently under development

* GEM333: T-cell engaging bispecific antibody (TCE) against CD33 in AML
* GEM3PSCA, TCE against PSCA in Prostate Cancer and other PSCA expressing solid tumours
* UniCAR-T-CD 123 for the treatment of AML, ALL and certain lymphomas
* UniCAR-T-PSMA for the treatment of a number of PSMA expressing tumours

## Literatur

* Nicola Mitwasi et al.: "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells In: Nature Scientific Reports, Band 10, 2020, S. 2141. doi:10.1038/s41598-020-59082-4, PMID 32034289.
* Loff, S., Meyer, J.-E., Dietrich, J., Spehr, J., Julia, R., von Bonin, M., Gründer, C., Franke, K., Feldmann, A., Bachmann, M., Ehninger, G., Ehninger, A., Cartellieri, M.: Late-Stage Preclinical Characterization of Switchable CD123-Specific CAR-T for Treatment of Acute Leukemia In: Blood, 132, 2018, S. 964-964. doi:10.1182/blood-2018-99-113288.
* Arndt, C., Feldmann, A., Koristka, S., Schafer, M., Bergmann, R., Mitwasi, N., Berndt, N., Bachmann, D., Kegler, A., Schmitz, M., Puentes-Cala, E., Soto, J.A., Ehninger, G., Pietzsch, J., Liolios, C., Wunderlich, G., Kotzerke, J., Kopka, K., Bachmann, M.: A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR In: Oncoimmunology, Band 8, 2019, Article: 1659095. doi:10.1080/2162402X.2019.1659095, PMID 31646084.
* C. Arndt, M. von Bonin et al.: Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. In: Leukemia, Band 27, Nummer 4, April 2013, S. 964–967, doi:10.1038/leu.2013.18, PMID 23325142.
